Chemotherapy and immunotherapy combo shows promise for aggressive lymphoma

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, has made a major breakthrough in treating a common and challenging form of cancer called diffuse large B-cell lymphoma (DLBCL).

Leave A Comment

Your email address will not be published. Required fields are marked *